Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.

Strehl S, König M, Boztug H, Cooper BW, Suzukawa K, Zhang SJ, Chen HY, Attarbaschi A, Dworzak MN.

Leukemia. 2013 Jul;27(7):1606-10. doi: 10.1038/leu.2012.371. Epub 2012 Dec 28. No abstract available.

PMID:
23271512
2.

Acute Promyelocytic Leukemia: A Review and Discussion of Variant Translocations.

Adams J, Nassiri M.

Arch Pathol Lab Med. 2015 Oct;139(10):1308-13. doi: 10.5858/arpa.2013-0345-RS. Review.

PMID:
26414475
3.

APL, a model disease for cancer therapies?

de Thé H, Chelbi-Alix MK.

Oncogene. 2001 Oct 29;20(49):7136-9. Review. No abstract available.

4.

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.

Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T.

Blood. 2011 Aug 11;118(6):1600-9. doi: 10.1182/blood-2011-01-329433. Epub 2011 May 25.

5.

Resistance to arsenic therapy in acute promyelocytic leukemia.

Zhu HH, Qin YZ, Huang XJ.

N Engl J Med. 2014 May 8;370(19):1864-6. doi: 10.1056/NEJMc1316382. No abstract available.

6.

Acute promyelocytic leukemia with a STAT5b-RARα fusion transcript defined by array-CGH, FISH, and RT-PCR.

Chen H, Pan J, Yao L, Wu L, Zhu J, Wang W, Liu C, Han Q, Du G, Cen J, Xue Y, Wu D, Sun M, Chen S.

Cancer Genet. 2012 Jun;205(6):327-31. doi: 10.1016/j.cancergen.2012.02.007.

PMID:
22749039
7.

[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].

Guo W, Wang H, Zhao W.

Zhonghua Yi Xue Za Zhi. 2000 May;80(5):327-31. Chinese.

PMID:
11798779
8.

Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.

Tong H, Li K, Mei C, Wang H, Chen Z, Jin J.

Ann Hematol. 2011 Dec;90(12):1493-4. doi: 10.1007/s00277-011-1210-7. Epub 2011 Mar 23. No abstract available.

PMID:
21431323
9.

Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.

Vitoux D, Nasr R, de The H.

Int J Biochem Cell Biol. 2007;39(6):1063-70. Epub 2007 Mar 21. Review.

PMID:
17468032
10.

Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.

Iaccarino L, Ottone T, Divona M, Cicconi L, Cairoli R, Voso MT, Lo-Coco F.

Br J Haematol. 2016 Mar;172(6):909-13. doi: 10.1111/bjh.13910. Epub 2016 Jan 5. Erratum in: Br J Haematol. 2016 Jul;174(2):335.

PMID:
26728337
11.

Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.

Shepshelovich D, Oniashvili N, Parnes D, Klein A, Muchtar E, Yeshaya J, Aviram A, Rabizadeh E, Raanani P.

Cancer Genet. 2015 Nov;208(11):575-9. doi: 10.1016/j.cancergen.2015.08.001. Epub 2015 Aug 20.

PMID:
26471811
12.

Resistance to therapy in acute promyelocytic leukemia.

Lehmann-Che J, Bally C, de Thé H.

N Engl J Med. 2014 Sep 18;371(12):1170-2. doi: 10.1056/NEJMc1409040. No abstract available.

13.

Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Nasr R, de Thé H.

Int J Hematol. 2010 Jun;91(5):742-7. doi: 10.1007/s12185-010-0582-0. Epub 2010 May 11.

PMID:
20455087
14.

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.

Lou Y, Ma Y, Sun J, Ye X, Pan H, Wang Y, Qian W, Meng H, Mai W, He J, Tong H, Jin J.

Ann Hematol. 2015 Nov;94(11):1829-37. doi: 10.1007/s00277-015-2477-x. Epub 2015 Aug 22.

PMID:
26294332
15.

The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance.

Abreu e Lima RS, Baruffi MR, de Lima AS, de Oliveira FM, de Figueiredo-Pontes LL, Tone LG, Rogatto SR, Falcao RP, Ferrari Chauffaille Mde L, Rego EM.

Br J Haematol. 2005 Feb;128(3):407-9. No abstract available.

PMID:
15667548
16.

Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia.

Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A, Tsuchiya S, Hatae Y, Fujimoto T, Kakizuka A, Konno T, Iinuma K.

Blood. 1998 Jul 15;92(2):374-82.

17.

Autophagic degradation of an oncoprotein.

Bøe SO, Simonsen A.

Autophagy. 2010 Oct;6(7):964-5. doi: 10.4161/auto.6.7.13066. Epub 2010 Oct 19.

PMID:
20724820
18.

Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.

Nichol JN, Garnier N, Miller WH Jr.

Best Pract Res Clin Haematol. 2014 Mar;27(1):19-31. doi: 10.1016/j.beha.2014.04.009. Epub 2014 May 2. Review.

PMID:
24907014
19.

[Acute promyelocytic leukemia with stat5b- RARα fusiongene: a case report and literatures review].

Liu L, Chen S, Tan J, Shi P, Chen K, Gao D, Huang X, Xie Y, Xu Y, Yang F, Qian S.

Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):68-9. doi: 10.3760/cma.j.issn.0253-2727.2016.01.014. Review. Chinese. No abstract available.

PMID:
26876258
20.

Acute promyelocytic leukemia in childhood.

Gregory J, Feusner J.

Curr Oncol Rep. 2009 Nov;11(6):439-45. Review.

PMID:
19840521

Supplemental Content

Support Center